Role of neuropeptides, neurotrophins, and neurohormones in skin wound healing

Wound Repair and Regeneration

Volumn 21, Issue 6, 2013, Pages 772-788

  Chéret, Jérémy ^a   Lebonvallet, Nicolas ^a   Carré, Jean Luc ^a   Misery, Laurent ^a,b   Le Gall Ianotto, Christelle ^a,b  

^a Laboratory of Neurosciences of Brest EA4685 University of Western Brittany   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; BETA ENDORPHIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GALANIN; GASTRIN RELEASING PEPTIDE; HYDROCORTISONE; LEUCINE ENKEPHALIN; METENKEPHALIN; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROHORMONE; NEUROKININ A; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTRANSMITTER; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; PEPTIDE HISTIDINE ISOLEUCINE; PEPTIDE HISTIDINE METHIONINE; PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE; PROLACTIN; PROOPIOMELANOCORTIN; SOMATOSTATIN; SUBSTANCE P; TACHYKININ; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NERVE GROWTH FACTOR;

CONFERENCE PAPER; HUMAN; MITOGENESIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NERVE CELL; SKIN CELL; SKIN INJURY; WOUND HEALING; ANIMAL; CELL COMMUNICATION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; IMMUNOLOGY; METABOLISM; NEUROGENIC INFLAMMATION; PATHOPHYSIOLOGY; PERIPHERAL NERVE; SKIN; SKIN DISEASE;

ANIMALS; CELL COMMUNICATION; HUMANS; NERVE GROWTH FACTORS; NEUROGENIC INFLAMMATION; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PERIPHERAL NERVES; SKIN; SKIN DISEASES; SKIN PHYSIOLOGICAL PHENOMENA; WOUND HEALING;

EID: 84888127660     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12101     Document Type: Conference Paper

References (255)

1. Boulais N, Pereira U, Lebonvallet N, Misery L,. The whole epidermis as the forefront of the sensory system. Exp Dermatol 2007; 16: 634-635.
2. Brazzini B, Ghersetich I, Hercogova J, Lotti T,. The neuro-immuno- cutaneous-endocrine network: relationship between mind and skin. Dermatol Ther 2003; 16: 123-131.
3. Boulais N, Misery L,. The epidermis: a sensory tissue. Eur J Dermatol 2008; 18: 119-127.
4. Wiesner-Menzel L, Schulz B, Vakilzadeh F, Czarnetzki BM,. Electron microscopical evidence for a direct contact between nerve fibres and mast cells. Acta Derm Venereol 1981; 61: 465-469.
5. Sueki H, Telegan B, Murphy GF,. Computer-assisted three-dimensional reconstruction of human dermal dendrocytes. J Invest Dermatol 1995; 105: 704-708.
6. Chateau Y, Misery L,. Connections between nerve endings and epidermal cells: are they synapses? Exp Dermatol 2004; 13: 2-4.
7. Gaudillere A, Misery L, Souchier C, Claudy A, Schmitt D,. Intimate associations between PGP9.5-positive nerve fibres and Langerhans cells. Br J Dermatol 1996; 135: 343-344.
8. Hilliges M, Wang L, Johansson O,. Ultrastructural evidence for nerve fibres within all vital layers of the human epidermis. J Invest Dermatol 1995; 104: 134-137.
9. Falanga V,. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
10. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V,. The tachykinin peptide family. Pharmacol Rev 2002; 54: 285-322.
11. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA,. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445-1463.
12. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T,. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139: 1479-1488.
13. Quinlan KL, Song IS, Bunnett NW, Letran E, Steinhoff M, Harten B, et al. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998; 275 (6 Pt 1): C1580-1590.
14. Liu J-Y, Hu J-H, Zhu Q-G, Li F-Q, Sun H-J,. Substance P receptor expression in human skin keratinocytes and fibroblasts. Br J Dermatol 2006; 155: 657-662.
15. Lembeck F, Holzer P,. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979; 310: 175-183.
16. Khalil Z, Helme R,. Sensory peptides as neuromodulators of wound healing in aged rats. J Gerontol A Biol Sci Med Sci 1996; 51: B354-361.
17. Delgado AV, McManus AT, Chambers JP,. Exogenous administration of Substance P enhances wound healing in a novel skin-injury model. Exp Biol Med (Maywood) 2005; 230: 271-280.
18. Scott JR, Muangman PR, Tamura RN, Zhu KQ, Liang Z, Anthony J, et al. Substance P levels and neutral endopeptidase activity in acute burn wounds and hypertrophic scar. Plast Reconstr Surg 2005; 115: 1095-1102.
19. Spenny ML, Muangman P, Sullivan SR, Bunnett NW, Ansel JC, Olerud JE, et al. Neutral endopeptidase inhibition in diabetic wound repair. Wound Repair Regen 2002; 10: 295-301.
20. Dunnick CA, Gibran NS, Heimbach DM,. Substance P has a role in neurogenic mediation of human burn wound healing. J Burn Care Rehabil 1996; 17: 390-396.
21. Kishimoto S,. The regeneration of substance P-containing nerve fibres in the process of burn wound healing in the guinea pig skin. J Invest Dermatol 1984; 83: 219-223.
22. Rook JM, Hasan W, McCarson KE,. Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression. Biochem Pharmacol 2009; 77: 1747-1755.
23. Altun V, Hakvoort TE, Van Zuijlen PP, Van der Kwast TH, Prens EP,. Nerve outgrowth and neuropeptide expression during the remodelling of human burn wound scars. A 7-month follow-up study of 22 patients. Burns 2001; 27: 717-722.
24. Holzer P,. Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 1998; 30: 5-11.
25. Hughes SR, Williams TJ, Brain SD,. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur J Pharmacol 1990; 191: 481-484.
26. Jain M, LoGerfo FW, Guthrie P, Pradhan L,. Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells. J Vasc Surg 2011; 53: 1654-1660.
27. Walsh DA, Hu DE, Mapp PI, Polak JM, Blake DR, Fan TP,. Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma. Histochem J 1996; 28: 759-769.
28. Wiedermann CJ, Auer B, Sitte B, Reinisch N, Schratzberger P, Kähler CM,. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol 1996; 298: 335-338.
29. Gibran NS, Tamura R, Tsou R, Isik FF,. Human dermal microvascular endothelial cells produce nerve growth factor: implications for wound repair. Shock 2003; 19: 127-130.
30. McGovern UB, Jones KT, Sharpe GR,. Intracellular calcium as a second messenger following growth stimulation of human keratinocytes. Br J Dermatol 1995; 132: 892-896.
31. Tanaka T, Danno K, Ikai K, Imamura S,. Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 1988; 90: 399-401.
32. Paus R, Heinzelmann T, Robicsek S, Czarnetzki BM, Maurer M,. Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995; 287: 500-502.
33. Nilsson J, Von Euler AM, Dalsgaard CJ,. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985; 315: 61-63.
34. Parenti A, Amerini S, Ledda F, Maggi CA, Ziche M,. The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 475-481.
35. Ziche M, Morbidelli L, Pacini M, Dolara P, Maggi CA,. NK1-receptors mediate the proliferative response of human fibroblasts to tachykinins. Br J Pharmacol 1990; 100: 11-14.
36. Lai X, Wang Z, Wei L, Wang L,. Effect of substance P released from peripheral nerve ending on endogenous expression of epidermal growth factor and its receptor in wound healing. Chin J Traumatol 2002; 5: 176-179.
37. Luger TA, Lotti T,. Neuropeptides: role in inflammatory skin diseases. J Eur Acad Dermatol Venereol 1998; 10: 207-211.
38. Wei T, Guo T-Z, Li W-W, Hou S, Kingery WS, Clark JD,. Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain. J Neuroinflammation 2012; 9: 181.
39. Ansel JC, Armstrong CA, Song I, Quinlan KL, Olerud JE, Caughman SW, et al. Interactions of the skin and nervous system. J Investig Dermatol Symp Proc 1997; 2: 23-26.
40. Delgado AV, McManus AT, Chambers JP,. Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides 2003; 37: 355-361.
41. Witte MB, Barbul A,. Role of nitric oxide in wound repair. Am J Surg 2002; 183: 406-412.
42. Benrath J, Zimmermann M, Gillardon F,. Substance P and nitric oxide mediate would healing of ultraviolet photodamaged rat skin: evidence for an effect of nitric oxide on keratinocyte proliferation. Neurosci Lett 1995; 200: 17-20.
43. Muangman P, Tamura RN, Muffley LA, Isik FF, Scott JR, Xie C, et al. Substance P enhances wound closure in nitric oxide synthase knockout mice. J Surg Res 2009; 153: 201-209.
44. Olerud JE, Usui ML, Seckin D, Chiu DS, Haycox CL, Song IS, et al. Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol 1999; 112: 873-881.
45. Scholzen TE, Luger TA,. Neutral endopeptidase and angiotensin-converting enzyme-key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 2004; 13 (Suppl. 4): 22-26.
46. Levy DM, Karanth SS, Springall DR, Polak JM,. Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study. Diabetologia 1989; 32: 427-433.
47. Antezana M, Sullivan SR, Usui M, Gibran N, Spenny M, Larsen J, et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 2002; 119: 1400-1404.
48. Pradhan L, Cai X, Wu S, Andersen ND, Martin M, Malek J, et al. Gene expression of pro-inflammatory cytokines and neuropeptides in diabetic wound healing. J Surg Res 2011; 167: 336-342.
49. Gibran NS, Jang YC, Isik FF, Greenhalgh DG, Muffley LA, Underwood RA, et al. Diminished neuropeptide levels contribute to the impaired cutaneous healing response associated with diabetes mellitus. J Surg Res 2002; 108: 122-128.
50. Scott JR, Tamura RN, Muangman P, Isik FF, Xie C, Gibran NS,. Topical substance P increases inflammatory cell density in genetically diabetic murine wounds. Wound Repair Regen 2008; 16: 529-533.
51. Younan G, Ogawa R, Ramirez M, Helm D, Dastouri P, Orgill DP,. Analysis of nerve and neuropeptide patterns in vacuum-assisted closure-treated diabetic murine wounds. Plast Reconstr Surg 2010; 126: 87-96.
52. Cao T, Grant AD, Gerard NP, Brain SD,. Lack of a significant effect of deletion of the tachykinin neurokinin-1 receptor on wound healing in mouse skin. Neuroscience 2001; 108: 695-700.
53. Wallengren J, Chen D, Neuropeptide-containing SF,. C-fibres and wound healing in rat skin. Neither capsaicin nor peripheral neurotomy affect the rate of healing. Br J Dermatol 1999; 140: 400-408.
54. Cavallini M, Casati A,. A prospective, randomized, blind comparison between saline, calcium gluconate and diphoterine for washing skin acid injuries in rats: effects on substance P and beta-endorphin release. Eur J Anaesthesiol 2004; 21: 389-392.
55. Burbach GJ, Kim KH, Zivony AS, Kim A, Aranda J, Wright S, et al. The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001; 117: 1075-1082.
56. Kellogg DL Jr,. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol 2006; 100: 1709-1718.
57. Tainio H, Vaalasti A, Rechardt L,. The distribution of substance P-, CGRP-, galanin- and ANP-like immunoreactive nerves in human sweat glands. Histochem J 1987; 19: 375-380.
58. Polak JM, Bloom SR,. Regulatory peptides-the distribution of two newly discovered peptides: PHI and NPY. Peptides 1984; 5 (Suppl. 1): 79-89.
59. Sterne GD, Brown RA, Green CJ, Terenghi G,. NT-3 modulates NPY expression in primary sensory neurons following peripheral nerve injury. J Anat 1998; 193 (Pt 2): 273-281.
60. Zhang WB, Domoto T, Tsumori T, Agawa S,. Nerve fibres containing neuropeptide Y in the atrioventricular valves of Japanese monkey and rat; a light and electron microscopic study. Histol Histopathol 1993; 8: 735-738.
61. Landry M, Holmberg K, Zhang X, Hökfelt T,. Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridation and immunohistochemistry. Exp Neurol 2000; 162: 361-384.
62. Rydh-Rinder M, Holmberg K, Elfvin LG, Wiesenfeld-Hallin Z, Hokfelt T,. Effects of peripheral axotomy on neuropeptides and nitric oxide synthase in dorsal root ganglia and spinal cord of the guinea pig: an immunohistochemical study. Brain Res 1996; 707: 180-188.
63. Ohara S, Tantuwaya V, DiStefano PS, Schmidt RE,. Exogenous NT-3 mitigates the transganglionic neuropeptide Y response to sciatic nerve injury. Brain Res 1995; 699: 143-148.
64. Onuoha GN, Alpar EK,. Levels of vasodilators (SP, CGRP) and vasoconstrictor (NPY) peptides in early human burns. Eur J Clin Invest 2001; 31: 253-257.
65. Crowe R, Parkhouse N, McGrouther D, Burnstock G,. Neuropeptide-containing nerves in painful hypertrophic human scar tissue. Br J Dermatol 1994; 130: 444-452.
66. Ahlborg G, Lundberg JM,. Exercise-induced changes in neuropeptide Y, noradrenaline and endothelin-1 levels in young people with type I diabetes. Clin Physiol 1996; 16: 645-655.
67. Kuncová J, Svíglerová J, Tonar Z, Slavíková J,. Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. Auton Neurosci 2005; 121: 7-15.
68. Ghersi G, Chen W, Lee EW, Zukowska Z,. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides 2001; 22: 453-458.
69. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-195.
70. Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z,. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 2006; 20: 1924-1926.
71. Hashim MA, Tadepalli AS,. Cutaneous vasomotor effects of neuropeptide Y. Neuropeptides 1995; 29: 263-271.
72. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander A-C, Hassani H, et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A 2003; 100: 6033-6038.
73. Caviedes-Bucheli J, Moreno GC, Lõpez MP, Bermeo-Noguera AM, Pacheco-Rodríguez G, Cuellar A, et al. Calcitonin gene-related peptide receptor expression in alternatively activated monocytes/macrophages during irreversible pulpitis. J Endod 2008; 34: 945-949.
74. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP,. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123: 398-410.
75. Hagner S, Stahl U, Knoblauch B, McGregor GP, Lang RE,. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 2002; 310: 41-50.
76. Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, et al. Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms. Pain 2011; 152: 2036-2051.
77. Hara M, Toyoda M, Yaar M, Bhawan J, Avila EM, Penner IR, et al. Innervation of melanocytes in human skin. J Exp Med 1996; 184: 1385-1395.
78. Gibbins IL, Wattchow D, Coventry B,. Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin. Brain Res 1987; 414: 143-148.
79. Toda M, Suzuki T, Hosono K, Kurihara Y, Kurihara H, Hayashi I, et al. Roles of calcitonin gene-related peptide in facilitation of wound healing and angiogenesis. Biomed Pharmacother 2008; 62: 352-359.
80. Engin C,. Effects of calcitonin gene-related peptide on wound contraction in denervated and normal rat skin: a preliminary report. Plast Reconstr Surg 1998; 101: 1887-1890.
81. Seike M, Ikeda M, Morimoto A, Matsumoto M, Kodama H,. Increased synthesis of calcitonin gene-related peptide stimulates keratinocyte proliferation in murine UVB-irradiated skin. J Dermatol Sci 2002; 28: 135-143.
82. Yu X-J, Li C-Y, Xu Y-H, Chen L-M, Zhou C-L,. Calcitonin gene-related peptide increases proliferation of human HaCaT keratinocytes by activation of MAP kinases. Cell Biol Int 2009; 33: 1144-1148.
83. Dallos A, Kiss M, Polyánka H, Dobozy A, Kemény L, Husz S,. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 2006; 40: 251-263.
84. Dahl J, Li J, Bring DK-I, Renström P, Ackermann PW,. Intermittent pneumatic compression enhances neurovascular ingrowth and tissue proliferation during connective tissue healing: a study in the rat. J Orthop Res 2007; 25: 1185-1192.
85. Yule KA, White SR,. Migration of 3T3 and lung fibroblasts in response to calcitonin gene-related peptide and bombesin. Exp Lung Res 1999; 25: 261-273.
86. Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J,. Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci U S A 1990; 87: 3299-3303.
87. Mapp PI, McWilliams DF, Turley MJ, Hargin E, Walsh DA,. A role for the sensory neuropeptide calcitonin gene-related peptide in endothelial cell proliferation in vivo. Br J Pharmacol 2012; 166: 1261-1271.
88. Brain SD, Grant AD,. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-934.
89. Jansen-Olesen I, Mortensen A, Edvinsson L,. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996; 16: 310-316.
90. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, et al. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993; 363: 159-163.
91. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC,. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998; 7: 81-96.
92. Niizeki H, Alard P, Streilein JW,. Calcitonin gene-related peptide is necessary for ultraviolet B-impaired induction of contact hypersensitivity. J Immunol 1997; 159: 5183-5186.
93. Kiss M, Kemény L, Gyulai R, Michel G, Husz S, Kovács R, et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. Inflammation 1999; 23: 557-567.
94. Chen B, Niu Y, Xie T, Miao M, Tian M, Ji X, et al. [Relationship between cutaneous glycometabolic disorders and cutaneous neuropathy in diabetic rats]. Zhonghua Shao Shang Za Zhi 2011; 27: 139-144.
95. Duckles SP,. Innervation of the cerebral vasculature. Ann Biomed Eng 1983; 11: 599-605.
96. Schulze E, Witt M, Fink T, Hofer A, Funk RH,. Immunohistochemical detection of human skin nerve fibres. Acta Histochem 1997; 99: 301-309.
97. Tachibana T, Nawa T,. Immunohistochemical reactions of receptors to met-enkephalin, VIP, substance P, and CGRP located on Merkel cells in the rat sinus hair follicle. Arch Histol Cytol 2005; 68: 383-391.
98. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J,. Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93: 126-138.
99. Kakurai M, Demitsu T, Umemoto N, Kobayashi Y, Inoue-Narita T, Fujita N, et al. Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. Br J Dermatol 2009; 161: 1232-1238.
100. Granoth R, Fridkin M, Gozes I,. VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. FEBS Lett 2000; 475: 78-83.
101. Wollina U, Huschenbeck J, Knöll B, Sternberg B, Hipler UC,. Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. Regul Pept 1997; 70: 29-36.
102. Yang J, Zong CH, Zhao ZH, Hu XD, Shi QD, Xiao XL, et al. Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis. Neuroscience 2009; 161: 413-421.
103. Collado B, Carmena MJ, Clemente C, Prieto JC, Bajo AM,. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 2007; 28: 1896-1901.
104. Yu X-J, Ren X-H, Xu Y-H, Chen L-M, Zhou C-L, Li C-Y,. Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway. Neuropeptides 2010; 44: 407-411.
105. Park YM, Kim CW,. The effects of substance P and vasoactive intestinal peptide on interleukin-6 synthesis in cultured human keratinocytes. J Dermatol Sci 1999; 22: 17-23.
106. Rayan GM, Johnson C, Pitha J, Cahill S, Said S,. Vasoactive intestinal peptide and nerve growth factor effects on nerve regeneration. J Okla State Med Assoc 1995; 88: 337-341.
107. Björklund H, Dalsgaard CJ, Jonsson CE, Hermansson A,. Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. Cell Tissue Res 1986; 243: 51-57.
108. Pincelli C, Fantini F, Romualdi P, Sevignani C, Lesa G, Benassi L, et al. Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992; 98: 421-427.
109. Giannetti A, Fantini F, Cimitan A, Pincelli C,. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176: 90-92.
110. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE,. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept 1999; 80: 49-55.
111. Fischer TC, Dinh QT, Peiser C, Löser C, Fischer A, Groneberg DA,. Simultaneous detection of receptor mRNA and ligand protein in human skin tissues. J Cutan Pathol 2002; 29: 65-71.
112. Cardell LO, Stjärne P, Wagstaff SJ, Agustí C, Nadel JA,. PACAP-induced plasma extravasation in rat skin. Regul Pept 1997; 71: 67-71.
113. Warren JB, Larkin SW, Coughlan M, Kajekar R, Williams TJ,. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol 1992; 106: 331-334.
114. Seeliger S, Buddenkotte J, Schmidt-Choudhury A, Rosignoli C, Shpacovitch V, Von Arnim U, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 2010; 177: 2563-2575.
115. Jongsma H, Danielsen N, Sundler F, Kanje M,. Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection. Brain Res 2000; 853: 186-196.
116. Zhang YZ, Hannibal J, Zhao Q, Moller K, Danielsen N, Fahrenkrug J, et al. Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: up-regulation after peripheral nerve injury. Neuroscience 1996; 74: 1099-1110.
117. Eedy DJ, Shaw C, Armstrong EP, Johnston CF, Buchanan KD,. Vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in human eccrine sweat glands: demonstration of innervation, specific binding sites and presence in secretions. Br J Dermatol 1990; 123: 65-76.
118. Weihe E, Hartschuh W,. Multiple peptides in cutaneous nerves: regulators under physiological conditions and a pathogenetic role in skin disease? Semin Dermatol 1988; 7: 284-300.
119. Takahashi K, Nakanishi S, Imamura S,. Direct effects of cutaneous neuropeptides on adenylyl cyclase activity and proliferation in a keratinocyte cell line: stimulation of cyclic AMP formation by CGRP and VIP/PHM, and inhibition by NPY through G protein-coupled receptors. J Invest Dermatol 1993; 101: 646-651.
120. Brazeau P,. Somatostatin: a peptide with unexpected physiologic activities. Am J Med 1986; 81 (6B): 8-13.
121. Patel YC,. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
122. Hagströmer L, Emtestam L, Stridsberg M, Talme T,. Expression pattern of somatostatin receptor subtypes 1-5 in human skin: an immunohistochemical study of healthy subjects and patients with psoriasis or atopic dermatitis. Exp Dermatol 2006; 15: 950-957.
123. Fantini F, Johansson O,. Neurochemical markers in human cutaneous Merkel cells. An immunohistochemical investigation. Exp Dermatol 1995; 4: 365-371.
124. Gaudillère A, Misery L, Bernard C, Souchier C, Claudy A, Schmitt D,. Presence of somatostatin in normal human epidermis. Br J Dermatol 1997; 137: 376-380.
125. Gaudillère A, Bernard C, Abello J, Schmitt D, Claudy A, Misery L,. Human normal dermal fibroblasts express somatostatin receptors. Exp Dermatol 1999; 8: 267-273.
126. Misery L, Gaudillère A, Claudy A, Schmitt D,. Expression of somatostatin on Langerhans cells. Adv Exp Med Biol 1995; 378: 109-110.
127. Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp H-J, Brandner JM,. Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. PLoS ONE 2011; 6: e19740.
128. Markovics A, Szoke É, Sándor K, Börzsei R, Bagoly T, Kemény Á, et al. Comparison of the anti-inflammatory and anti-nociceptive effects of cortistatin-14 and somatostatin-14 in distinct in vitro and in vivo model systems. J Mol Neurosci 2012; 46: 40-50.
129. Pintér E, Helyes Z, Szolcsányi J,. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 2006; 112: 440-456.
130. Helyes Z, Thán M, Oroszi G, Pintér E, Németh J, Kéri G, et al. Anti-nociceptive effect induced by somatostatin released from sensory nerve terminals and by synthetic somatostatin analogues in the rat. Neurosci Lett 2000; 278: 185-188.
131. Green PG, Basbaum AI, Levine JD,. Sensory neuropeptide interactions in the production of plasma extravasation in the rat. Neuroscience 1992; 50: 745-749.
132. Payan DG, Hess CA, Goetzl EJ,. Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol 1984; 84: 433-438.
133. Stanisz AM, Befus D, Bienenstock J,. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 1986; 136: 152-156.
134. García de la Torre N, Wass JAH, Turner HE,. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57: 425-441.
135. Senapati A, Anand P, McGregor GP, Ghatei MA, Thompson RP, Bloom SR,. Depletion of neuropeptides during wound healing in rat skin. Neurosci Lett 1986; 71: 101-105.
136. Sun Y-G, Chen Z-F,. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007; 448: 700-703.
137. Panula P, Hadjiconstantinou M, Yang HY, Costa E,. Immunohistochemical localization of bombesin/gastrin-releasing peptide and substance P in primary sensory neurons. J Neurosci 1983; 3: 2021-2029.
138. Tominaga M, Ogawa H, Takamori K,. Histological characterization of cutaneous nerve fibres containing gastrin-releasing peptide in NC/Nga mice: an atopic dermatitis model. J Invest Dermatol 2009; 129: 2901-2905.
139. Staniek V, Misery L, Peguet-Navarro J, Sabido O, Cuber JC, Dezutter-Dambuyant C, et al. Expression of gastrin-releasing peptide receptor in human skin. Acta Derm Venereol 1996; 76: 282-286.
140. Andoh T, Kuwazono T, Lee J-B, Kuraishi Y,. Gastrin-releasing peptide induces itch-related responses through mast cell degranulation in mice. Peptides 2011; 32: 2098-2103.
141. Baroni A, Perfetto B, Canozo N, Braca A, Farina E, Melito A, et al. Bombesin: a possible role in wound repair. Peptides 2008; 29: 1157-1166.
142. Regauer S, Compton CC,. Cultured keratinocyte sheets enhance spontaneous re-epithelialization in a dermal explant model of partial-thickness wound healing. J Invest Dermatol 1990; 95: 341-346.
143. Yamaguchi Y, Hosokawa K, Nakatani Y, Sano S, Yoshikawa K, Itami S,. Gastrin-releasing peptide, a bombesin-like neuropeptide, promotes cutaneous wound healing. Dermatol Surg 2002; 28: 314-319.
144. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A 2006; 103: 7759-7764.
145. Hartschuh W, Weihe E, Reinecke M,. Peptidergic (neurotensin, VIP, substance P) nerve fibres in the skin. Immunohistochemical evidence of an involvement of neuropeptides in nociception, pruritus and inflammation. Br J Dermatol 1983; 109 (Suppl. 25): 14-17.
146. Da Silva L, Neves BM, Moura L, Cruz MT, Carvalho E,. Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression. Biochim Biophys Acta 2011; 1813: 1863-1871.
147. Haase I, Czarnetzki BM, Rosenbach T,. Thrombin and melittin activate phospholipase C in human HaCaT keratinocytes. Exp Dermatol 1996; 5: 84-88.
148. Bauer JW, Lang R, Jakab M, Kofler B,. Galanin family of peptides in skin function. Cell Mol Life Sci 2008; 65: 1820-1825.
149. Kofler B, Berger A, Santic R, Moritz K, Almer D, Tuechler C, et al. Expression of neuropeptide galanin and galanin receptors in human skin. J Invest Dermatol 2004; 122: 1050-1053.
150. Johansson O, Fantini F, Hu H,. Neuronal structural proteins, transmitters, transmitter enzymes and neuropeptides in human Meissner's corpuscles: a reappraisal using immunohistochemistry. Arch Dermatol Res 1999; 291: 419-424.
151. Santic R, Schmidhuber SM, Lang R, Rauch I, Voglas E, Eberhard N, et al. Alarin is a vasoactive peptide. Proc Natl Acad Sci U S A 2007; 104: 10217-10222.
152. Ji RR, Zhang X, Zhang Q, Dagerlind A, Nilsson S, Wiesenfeld-Hallin Z, et al. Central and peripheral expression of galanin in response to inflammation. Neuroscience 1995; 68: 563-576.
153. Dallos A, Kiss M, Polyánka H, Dobozy A, Kemény L, Husz S,. Galanin receptor expression in cultured human keratinocytes and in normal human skin. J Peripher Nerv Syst 2006; 11: 156-164.
154. Hökfelt T, Wiesenfeld-Hallin Z, Villar M, Melander T,. Increase of galanin-like immunoreactivity in rat dorsal root ganglion cells after peripheral axotomy. Neurosci Lett 1987; 83: 217-220.
155. Hökfelt T, Zhang X, Wiesenfeld-Hallin Z,. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci 1994; 17: 22-30.
156. Holmes FE, Mahoney S-A, Wynick D,. Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 2005; 39: 191-199.
157. Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE, et al. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 2005; 280: 22564-22571.
158. Trejter M, Brelinska R, Warchol JB, Butowska W, Neri G, Rebuffat P, et al. Effects of galanin on proliferation and apoptosis of immature rat thymocytes. Int J Mol Med 2002; 10: 183-186.
159. Jimenez-Andrade JM, Zhou S, Yamani A, Valencia de Ita S, Castañeda-Hernandez G, Carlton SM,. Mechanism by which peripheral galanin increases acute inflammatory pain. Brain Res 2005; 1056: 113-117.
160. Schmidhuber SM, Santic R, Tam CW, Bauer JW, Kofler B, Brain SD,. Galanin-like peptides exert potent vasoactive functions in vivo. J Invest Dermatol 2007; 127: 716-721.
161. Sántha P, Pierau FK, Jancsõ G,. Evidence for an inhibition by endogenous galanin of neurogenic cutaneous vasodilatation in the pigeon. Neurosci Lett 1998; 243: 101-104.
162. Chao MV, Bothwell MA, Ross AH, Koprowski H, Lanahan AA, Buck CR, et al. Gene transfer and molecular cloning of the human NGF receptor. Science 1986; 232: 518-521.
163. Dechant G,. Molecular interactions between neurotrophin receptors. Cell Tissue Res 2001; 305: 229-238.
164. Vos P, Stark F, Pittman RN,. Merkel cells in vitro: production of nerve growth factor and selective interactions with sensory neurons. Dev Biol 1991; 144: 281-300.
165. Bull HA, Leslie TA, Chopra S, Dowd PM,. Expression of nerve growth factor receptors in cutaneous inflammation. Br J Dermatol 1998; 139: 776-783.
166. Shibayama E, Koizumi H,. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996; 148: 1807-1818.
167. Welker P, Grabbe J, Grützkau A, Henz BM,. Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology 1998; 94: 310-317.
168. Raychaudhuri SK, Raychaudhuri SP, Weltman H, Farber EM,. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res 2001; 293: 291-295.
169. Marconi A, Terracina M, Fila C, Franchi J, Bonté F, Romagnoli G, et al. Expression and function of neurotrophins and their receptors in cultured human keratinocytes. J Invest Dermatol 2003; 121: 1515-1521.
170. Marconi A, Panza MC, Bonnet-Duquennoy M, Lazou K, Kurfurst R, Truzzi F, et al. Expression and function of neurotrophins and their receptors in human melanocytes. Int J Cosmet Sci 2006; 28: 255-261.
171. Palazzo E, Marconi A, Truzzi F, Dallaglio K, Petrachi T, Humbert P, et
172. Davies AM, Bandtlow C, Heumann R, Korsching S, Rohrer H, Thoenen H,. Timing and site of nerve growth factor synthesis in developing skin in relation to innervation and expression of the receptor. Nature 1987; 326: 353-358.
173. Pincelli C, Sevignani C, Manfredini R, Grande A, Fantini F, Bracci-Laudiero L, et al. Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol 1994; 103: 13-18.
174. Kawamoto K, Matsuda H,. Nerve growth factor and wound healing. Prog Brain Res 2004; 146: 369-384.
175. Di Marco E, Mathor M, Bondanza S, Cutuli N, Marchisio PC, Cancedda R, et al. Nerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stimulates their growth by a novel autocrine loop. J Biol Chem 1993; 268: 22838-22846.
176. Pincelli C, Marconi A,. Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci 2000; 22: 71-79.
177. Shi C-M, Qu J-F, Cheng T-M,. Effects of the nerve growth factor on the survival and wound healing in mice with combined radiation and wound injury. J Radiat Res 2003; 44: 223-228.
178. Nithya M, Suguna L, Rose C,. The effect of nerve growth factor on the early responses during the process of wound healing. Biochim Biophys Acta 2003; 1620: 25-31.
179. Li AK, Koroly MJ, Schattenkerk ME, Malt RA, Young M,. Nerve growth factor: acceleration of the rate of wound healing in mice. Proc Natl Acad Sci U S A 1980; 77: 4379-4381.
180. Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 2001; 98: 6162-6167.
181. Micera A, Lambiase A, Stampachiacchiere B, Sgrulletta R, Normando EM, Bonini S, et al. Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. Mol Vis 2007; 13: 981-987.
182. Lewin GR, Mendell LM,. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353-359.
183. Matsuda H, Koyama H, Sato H, Sawada J, Itakura A, Tanaka A, et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 1998; 187: 297-306.
184. Schmidt Y, Unger JW, Bartke I, Reiter R,. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995; 132: 16-23.
185. Park KA, Fehrenbacher JC, Thompson EL, Duarte DB, Hingtgen CM, Vasko MR,. Signaling pathways that mediate nerve growth factor-induced increase in expression and release of calcitonin gene-related peptide from sensory neurons. Neuroscience 2010; 171: 910-923.
186. Aloe L, Tirassa P, Lambiase A,. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008; 57: 253-258.
187. Sun W, Lin H, Chen B, Zhao W, Zhao Y, Xiao Z, et al. Collagen scaffolds loaded with collagen-binding NGF-beta accelerate ulcer healing. J Biomed Mater Res A 2010; 92: 887-895.
188. Terenghi G, Mann D, Kopelman PG, Anand P,. trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997; 228: 33-36.
189. Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J,. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000; 114: 1108-1112.
190. Cartwright M, Mikheev AM, Heinrich G,. Expression of neurotrophin genes in human fibroblasts: differential regulation of the brain-derived neurotrophic factor gene. Int J Dev Neurosci 1994; 12: 685-693.
191. Botchkarev VA, Botchkarev NV, Albers KM, Van der Veen C, Lewin GR, Paus R,. Neurotrophin-3 involvement in the regulation of hair follicle morphogenesis. J Invest Dermatol 1998; 111: 279-285.
192. Beggs S, Alvares D, Moss A, Currie G, Middleton J, Salter MW, et al. A role for NT-3 in the hyperinnervation of neonatally wounded skin. Pain 2012; 153: 2133-2139.
193. Sterne GD, Brown RA, Green CJ, Terenghi G,. Neurotrophin-3 delivered locally via fibronectin mats enhances peripheral nerve regeneration. Eur J Neurosci 1997; 9: 1388-1396.
194. Botchkarev VA, Metz M, Botchkareva NV, Welker P, Lommatzsch M, Renz H, et al. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. Lab Invest 1999; 79: 557-572.
195. Truzzi F, Marconi A, Atzei P, Panza MC, Lotti R, Dallaglio K, et al. p75 neurotrophin receptor mediates apoptosis in transit-amplifying cells and its overexpression restores cell death in psoriatic keratinocytes. Cell Death Differ 2011; 18: 948-958.
196. Kryl D, Barker PA,. TTIP is a novel protein that interacts with the truncated T1 TrkB neurotrophin receptor. Biochem Biophys Res Commun 2000; 279: 925-930.
197. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H, et al. Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin αVβ3-FAK cascade. J Cell Physiol 2012; 227: 2123-2129.
198. Sun C, Hu Y, Chu Z, Huang J, Zhang L,. The effect of brain-derived neurotrophic factor on angiogenesis. J Huazhong Univ Sci Technol Med Sci 2009; 29: 139-143.
199. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP,. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991; 254: 421-423.
200. Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, Wortsman J,. Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology 2004; 145: 941-950.
201. Cao J, Cetrulo CL, Theoharides TC,. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 2006; 69: 998-1006.
202. Zbytek B, Pfeffer LM, Slominski AT,. Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes. J Invest Dermatol 2003; 121: 1496-1499.
203. Zbytek B, Mysliwski A, Slominski A, Wortsman J, Wei ET, Mysliwska J,. Corticotropin-releasing hormone affects cytokine production in human HaCaT keratinocytes. Life Sci 2002; 70: 1013-1021.
204. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J,. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 2005; 162: 97-102.
205. Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC,. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009; 160: 345-352.
206. Zbytek B, Slominski AT,. Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol 2005; 203: 118-126.
207. Slominski A, Wortsman J, Luger T, Paus R, Solomon S,. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000; 80: 979-1020.
208. Rassouli O, Liapakis G, Lazaridis I, Sakellaris G, Gkountelias K, Gravanis A, et al. A novel role of peripheral corticotropin-releasing hormone (CRH) on dermal fibroblasts. PLoS ONE 2011; 6: e21654.
209. Slominski A, Zbytek B, Szczesniewski A, Wortsman J,. Cultured human dermal fibroblasts do produce cortisol. J Invest Dermatol 2006; 126: 1177-1178.
210. Wintzen M, Gilchrest BA,. Proopiomelanocortin, its derived peptides, and the skin. J Invest Dermatol 1996; 106: 3-10.
211. Bicknell AB,. The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol 2008; 20: 692-699.
212. Mountjoy KG,. The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides. Mol Cell Endocrinol 1994; 102: R7-11.
213. Rousseau K, Kauser S, Pritchard LE, Warhurst A, Oliver RL, Slominski A, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J 2007; 21: 1844-1856.
214. Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, Shuster S,. MSH peptides are present in mammalian skin. Peptides 1983; 4: 813-816.
215. Matsumoto K, Robb E, Warden G, Nordlund J,. Hyperpigmentation of human skin grafted on to athymic nude mice: immunohistochemical study. Br J Dermatol 1996; 135: 412-418.
216. Muffley LA, Zhu KQ, Engrav LH, Gibran NS, Hocking AM,. Spatial and temporal localization of the melanocortin 1 receptor and its ligand α-melanocyte-stimulating hormone during cutaneous wound repair. J Histochem Cytochem 2011; 59: 278-288.
217. Tsatmali M, Ancans J, Yukitake J, Thody AJ,. Skin POMC peptides: their actions at the human MC-1 receptor and roles in the tanning response. Pigment Cell Res 2000; 13 (Suppl. 8): 125-129.
218. Luger TA, Brzoska T, Scholzen TE, Kalden DH, Sunderkötter C, Armstrong C, et al. The role of alpha-MSH as a modulator of cutaneous inflammation. Ann N Y Acad Sci 2000; 917: 232-238.
219. Böhm M, Schulte U, Kalden H, Luger TA,. Alpha-melanocyte-stimulating hormone modulates activation of NF-kappa B and AP-1 and secretion of interleukin-8 in human dermal fibroblasts. Ann N Y Acad Sci 1999; 885: 277-286.
220. Apkarian RP, Curtis JC,. Hormonal regulation of capillary fenestrae in the rat adrenal cortex: quantitative studies using objective lens staging scanning electron microscopy. Scan Electron Microsc 1986; (Pt 4): 1381-1393.
221. Gaillard I, Keramidas M, Liakos P, Vilgrain I, Feige JJ, Vittet D,. ACTH-regulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature. J Cell Physiol 2000; 185: 226-234.
222. Zanello SB, Jackson DM, Holick MF,. An immunocytochemical approach to the study of beta-endorphin production in human keratinocytes using confocal microscopy. Ann N Y Acad Sci 1999; 885: 85-99.
223. Farooqui JZ, Medrano EE, Abdel-Malek Z, Nordlund J,. The expression of proopiomelanocortin and various POMC-derived peptides in mouse and human skin. Ann N Y Acad Sci 1993; 680: 508-510.
224. Skobowiat C, Dowdy JC, Sayre RM, Tuckey RC, Slominski A,. Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. Am J Physiol Endocrinol Metab 2011; 301: E484-493.
225. Wintzen M, Ostijn DM, Polderman MC, Le Cessie S, Burbach JP, Vermeer BJ,. Total body exposure to ultraviolet radiation does not influence plasma levels of immunoreactive beta-endorphin in man. Photodermatol Photoimmunol Photomed 2001; 17: 256-260.
226. Bigliardi PL, Sumanovski LT, Büchner S, Rufli T, Bigliardi-Qi M,. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J Invest Dermatol 2003; 120: 145-152.
227. Gold LI, Sung JJ, Siebert JW, Longaker MT,. Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. Am J Pathol 1997; 150: 209-222.
228. Bigliardi PL, Büchner S, Rufli T, Bigliardi-Qi M,. Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. J Recept Signal Transduct Res 2002; 22: 191-199.
229. Cheng B, Liu H, Fu X, Sheng Z, Qiu J, Cao R,. [Expression of beta-endorphin and micro-opioid receptor during wound healing process in rat with deep partial-thickness scald]. Zhonghua Shao Shang Za Zhi 2007; 23: 36-39.
230. Cirillo N, Prime SS,. Keratinocytes synthesize and activate cortisol. J Cell Biochem 2011; 112: 1499-1505.
231. Terao M, Murota H, Kimura A, Kato A, Ishikawa A, Igawa K, et al. 11β-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. PLoS ONE 2011; 6: e25039.
232. Vukelic S, Stojadinovic O, Pastar I, Rabach M, Krzyzanowska A, Lebrun E, et al. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J Biol Chem 2011; 286: 10265-10275.
233. Hannen RF, Michael AE, Jaulim A, Bhogal R, Burrin JM, Philpott MP,. Steroid synthesis by primary human keratinocytes; implications for skin disease. Biochem Biophys Res Commun 2011; 404: 62-67.
234. Christian LM, Graham JE, Padgett DA, Glaser R, Kiecolt-Glaser JK,. Stress and wound healing. Neuroimmunomodulation 2006; 13: 337-346.
235. Ebrecht M, Hextall J, Kirtley L-G, Taylor A, Dyson M, Weinman J,. Perceived stress and cortisol levels predict speed of wound healing in healthy male adults. Psychoneuroendocrinology 2004; 29: 798-809.
236. Altemus M, Rao B, Dhabhar FS, Ding W, Granstein RD,. Stress-induced changes in skin barrier function in healthy women. J Invest Dermatol 2001; 117: 309-317.
237. Detillion CE, Craft TKS, Glasper ER, Prendergast BJ, DeVries AC,. Social facilitation of wound healing. Psychoneuroendocrinology 2004; 29: 1004-1011.
238. Alberti LR, Vasconcellos LdeS, Petroianu A,. Influence of local or systemic corticosteroids on skin wound healing resistance. Acta Cir Bras 2012; 27: 295-299.
239. Pratsinis H, Dimozi A, Pilichos K, Tsagarakis S, Yiacoumettis AM, Kletsas D,. Previous chronic exogenous glucocorticoid administration in vivo does not affect functional characteristics and cellular lifespan of human skin fibroblasts in vitro. Exp Dermatol 2011; 20: 529-531.
240. Hübner G, Brauchle M, Smola H, Madlener M, Fässler R, Werner S,. Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokinel 1996; 8: 548-556.
241. Glaser R, Kiecolt-Glaser JK, Marucha PT, MacCallum RC, Laskowski BF, Malarkey WB,. Stress-related changes in proinflammatory cytokine production in wounds. Arch Gen Psychiatry 1999; 56: 450-456.
242. Foitzik K, Langan EA, Paus R,. Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol 2009; 129: 1071-1087.
243. Richards RG, Hartman SM,. Human dermal fibroblast cells express prolactin in vitro. J Invest Dermatol 1996; 106: 1250-1255.
244. Merkle CJ, Schuler LA, Schaeffer RC Jr, Gribbon JM, Montgomery DW,. Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine 2000; 13: 37-46.
245. Clapp C, Aranda J, González C, Jeziorski MC, Martínez de la Escalera G,. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 2006; 17: 301-307.
246. Brizio-Molteni L, Molteni A, Warpeha RL, Angelats J, Lewis N, Fors EM,. Prolactin, corticotropin, and gonadotropin concentrations following thermal injury in adults. J Trauma 1984; 24: 1-7.
247. Slominski AT, Zmijewski MA, Zbytek B, Brozyna AA, Granese J, Pisarchik A, et al. Regulated proenkephalin expression in human skin and cultured skin cells. J Invest Dermatol 2011; 131: 613-622.
248. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ,. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met(5)]enkephalin. Brain Res 1999; 849: 147-154.
249. Zagon IS, Wu Y, McLaughlin PJ,. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol 1996; 106: 490-497.
250. Bigliardi-Qi M, Gaveriaux-Ruff C, Zhou H, Hell C, Bady P, Rufli T, et al. Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 2006; 74: 174-185.
251. Nissen JB, Kragballe K,. Enkephalins modulate differentiation of normal human keratinocytes in vitro. Exp Dermatol 1997; 6: 222-229.
252. Zagon IS, Sassani JW, McLaughlin PJ,. Reepithelialization of the human cornea is regulated by endogenous opioids. Invest Ophthalmol Vis Sci 2000; 41: 73-81.
253. McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS,. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. Am J Physiol Regul Integr Comp Physiol 2012; 302: R1084-1090.
254. Kohl A, Werner A, Buntrock P, Diezel W, Adrian K, Titov MI,. [The effect of the peptide dalargin on wound healing]. Dermatol Monatsschr 1989; 175: 561-572.
255. Vinogradov VA, Spevak SE, Larygin KN, Korobov NV, Solov'eva AI,. [Opioid activity of peptides and wound healing of the skin]. Biull Eksp Biol Med 1987; 104: 89-91.